London School of Hygiene and Tropical Medicine
- Country
- 🇧🇪Belgium
- Ownership
- Private
- Established
- 1899-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.lshtm.ac.uk
Clinical Trials
295
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (257 trials with phase data)• Click on a phase to view related trials
Serological Testing and Treatment for Plasmodium Vivax Malaria: a Trial in Ethiopia and Madagascar
- Conditions
- Malaria VivaxPlasmodium FalciparumMalaria FalciparumPlasmodium Vivax
- First Posted Date
- 2025-04-11
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- London School of Hygiene and Tropical Medicine
- Target Recruit Count
- 19200
- Registration Number
- NCT06923592
- Locations
- 🇪🇹
Armauer Hansen Research Institute, Addis Ababa, Ethiopia
🇲🇬Institut Pasteur de Madagascar, Antananarivo, Madagascar
Comprehensive Ambulatory Antibiotics for the Treatment of Congenital Syphilis
- Conditions
- Syphilis, Congenital
- Interventions
- First Posted Date
- 2025-04-10
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- London School of Hygiene and Tropical Medicine
- Target Recruit Count
- 90
- Registration Number
- NCT06921213
- Locations
- 🇮🇩
Universitas Indonesia, Jakarta, Indonesia
🇲🇼Malawi Liverpool Wellcome Programme, Blantyre, Malawi
🇿🇦Stellenbosch, Stellenbosch, South Africa
Evaluating the Individual and Combined Effects of Hand Hygiene Promotion and Hardware Provision on Handwashing With Soap in Lusaka, Zambia
- Conditions
- Handwashing Behaviour
- First Posted Date
- 2025-03-07
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- London School of Hygiene and Tropical Medicine
- Target Recruit Count
- 1800
- Registration Number
- NCT06865495
- Locations
- 🇿🇲
Centre for Infectious Disease Research in Zambia (CIDRZ), Lusaka, Zambia
A Health App Using Recipes and Education Components to Facilitate Sustainable and Healthier Diets.
- Conditions
- NutritionSustainabilityMobile Health Technology (mHealth)
- First Posted Date
- 2025-02-19
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- London School of Hygiene and Tropical Medicine
- Target Recruit Count
- 99
- Registration Number
- NCT06833736
- Locations
- 🇬🇧
London School of Hygiene & Tropical Medicine, London, United Kingdom
Seasonal R21 Mass Vaccination for Malaria Elimination
- Conditions
- Malaria
- First Posted Date
- 2024-08-29
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- London School of Hygiene and Tropical Medicine
- Target Recruit Count
- 16200
- Registration Number
- NCT06578572
- Locations
- 🇧🇫
Clinical Research Unit of Nanoro, Burkina Faso, Nanoro, Burkina Faso
🇬🇲MRC Unit The Gambia at LSHTM, Fajara, Gambia
- Prev
- 1
- 2
- 3
- 4
- 5
- 59
- Next
News
Novartis Receives Approval for First Malaria Treatment Designed for Newborns and Young Infants
Novartis has received Swiss regulatory approval for Coartem Baby, the first malaria treatment specifically formulated for newborns and infants weighing 2-5 kilograms.
NHS England Launches World-First Gonorrhoea Vaccine Amid Record Infection Rates
England becomes the first country globally to implement a gonorrhoea vaccination program, targeting high-risk populations as infections reach record levels with over 85,000 cases reported in 2023.
USAID Funding Freeze Threatens Global Clinical Trials and Infectious Disease Research
The US Agency for International Development (USAID) has suspended all foreign assistance funding, forcing the pause of multiple clinical trials and threatening ongoing research in HIV, tuberculosis, and malaria.
Large-Scale Study Finds No Significant Link Between Psoriasis and Alzheimer's Risk, But Notes Slight Increase in Vascular Dementia
A comprehensive study of over 2.1 million individuals reveals that psoriasis patients do not face significantly higher risks of Alzheimer's disease, contradicting previous conflicting research findings.
Real-World Data Emulation Study Challenges Clinical Trial Findings on Apixaban and Warfarin
Researchers emulated a clinical trial using real-world data to compare apixaban and warfarin for stroke prevention in atrial fibrillation patients.